ICEECE2012 Poster Presentations Cardiovascular Endocrinology and Lipid Metabolism (74 abstracts)
Psoriasis is associated with decreased adiponectin levels beyond cardiovascular and metabolic risk factors
R. Li , P. Krishnamoorthy , Y. Yu , A. Raper , A. Baer , S. Derohannessian , M. Wilcox , A. Vorohees , M. Reilly , D. Rader , J. Gelfand & N. Mehta
University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Introduction: Psoriasis is a systemic inflammatory skin disease, which is associated with increased cardiovascular disease (CVD) potentially through metabolic derangements due to chronic inflammation. Serum adiponectin appears to decrease the risk of CVD and has been shown to negatively associate with waist size and insulin resistance (IR), both of which are increased in psoriasis. It is unknown, however, if psoriasis is associated with decreased adiponectin levels beyond traditional CVD and metabolic risk factors.
Methods: We prospectively enrolled a consecutive sample of patients with psoriasis (n=122) and compared cardiometabolic risk factors with an asymptomatic sample without psoriasis from our practice (n=129). Fasting lipids, insulin, glucose, and total plasma adiponectin were measured by commercial assays. HOMA-IR was used to estimate IR. We performed stepwise multivariable linear regression adjusting for CVD (age, gender, smoking status, hypertension, lipids) and metabolic (HOMA-IR, waist size, triglycerides) risk factors using STATA12 software.
Results: Psoriasis patients were more insulin resistant (HOMA-IR: 3.5 (2.3–6.6) vs 1.4 (0.94–2.1), P<0.001) and had higher waist sizes (40 (35–44) vs 35.5 (33–39.5), P<0.001) than patients without psoriasis. Total serum adiponectin was lower in psoriasis than controls (7.1 (4.9–11.3) vs 14.5 (8.4–24.2), β=−0.59, P<0.001), even after adjustment for CVD (β=−0.56, P<0.001) and metabolic variables (β=−0.49, P<0.001).
Conclusion: Total serum adiponectin levels are lower in psoriasis patients compared to healthy controls, even after adjustment for CVD and metabolic risk factors. These results suggest that decreased adiponectin levels are a unique feature of psoriasis pathophysiology, which may play a role in the increased risk of CVD. Larger prospective studies looking at CVD outcomes and effects of psoriasis treatment on adiponectin are warranted.
Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.
Funding: This work was supported, however funding details unavailable.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more